When does the patent for mounjaro expire?

Understanding Mounjaro's Patent Exclusivity

Mounjaro (tirzepatide) is a recently approved medication for type 2 diabetes treatment and weight management. As a newly launched product, it's essential to understand its patent landscape. Mounjaro is developed by Eli Lilly and Company, and its patent status plays a crucial role in determining market availability and competition in the pharmaceutical industry.

Patent Expiration Timeline

The United States Patent and Trademark Office (USPTO) is the primary authority for patent-related information in the United States. According to [1] DrugPatentWatch.com, the patent exclusivity for Mounjaro (tirzepatide) extends until September 2031. This means that Eli Lilly and Company, the developer of Mounjaro, enjoys an exclusive market position for the medication until 2031. However, patent expiration triggers the entry of biosimilars and generic medications into the market, which can be approved for launch as early as one year prior to patent expiration, if the patent holder is unable to delay biosimilar entry by additional regulatory hurdles and appeals.

Biosimilar Competition and Regulatory Hurdles

Once the Mounjaro patent expires, companies can file for biosimilar applications, seeking approval to market alternative versions of the medication. To expedite this process, manufacturers might consider pursuing the 351(k) pathway, also known as the abbreviated biosimilar pathway, which provides for faster approval times based on existing safety and efficacy data [2]. However, the regulatory approval process is subject to change, and there could be further litigation over patent extensions or biosimilar validity.

Future Market Dynamics

The patent expiration timeline will impact the market availability and pricing dynamics of Mounjaro. As competition from biosimilar manufacturers enters the market, patients, healthcare providers, and payers can expect increased generic options, which may lead to reduced costs and increased access to medication [3].

Sources:
[1] DrugPatentWatch.com. (N.d.). Tirzepatide – Eli Lilly and Company. Retrieved from https://www.drugpatentwatch.com/result.php?q=tirzepatide&searchtype=genericname&company=Eli Lilly and Company
[2] FDA.gov. (2022). Biosimilar Development. Retrieved from https://www.fda.gov/drugs/biosimilar-and-interchangeable-biologics/biosimilar-development
[3] FDA.gov. (2022). Generic Drugs. Retrieved from https://www.fda.gov/drugs/quality-and-manufacturing/generic-drugs